How Employers Dropping GLP-1 Coverage Affects Out-of-Pocket Costs: A 2027 Planning Guide

With GLP-1 drug costs climbing sharply, a growing number of employers are reconsidering or eliminating coverage for medications like Ozempic and Wegovy heading into 2027 benefit cycles. If your employer drops this coverage, your monthly out-of-pocket costs could jump from a modest copay to well over $1,000 per month overnight.

Why Employers Are Reconsidering GLP-1 Coverage in 2027

The financial math behind GLP-1 coverage has become increasingly difficult for employers to justify. According to data tracked by Employee Benefit News and multiple benefits consulting firms, GLP-1 medications now represent one of the fastest-growing line items in employer health plan budgets — despite covering a relatively small percentage of the enrolled workforce.

The average annual cost of Wegovy (semaglutide 2.4mg) sits around $16,000 to $17,000 per patient per year at list price, before any rebates or negotiations. For a mid-sized employer with even 3–5% of employees using a GLP-1 drug, that translates to a meaningful six-figure burden on the plan annually.

The Benefit Year 2027 Inflection Point

Open enrollment periods for the 2027 plan year begin for most employees in fall 2026. That means employers making coverage decisions right now — in 2025 — will be locking in policies that employees won't feel until months later. The lag between a policy decision and real-world financial impact is part of what makes this trend particularly difficult for patients to anticipate and plan around.

According to surveys cited in recent industry reporting, a significant share of large employers that currently cover GLP-1 drugs for weight management are actively evaluating whether to continue that coverage, cap it with stricter prior authorization criteria, or eliminate it entirely by 2027.

What "Dropping Coverage" Actually Means for Your Wallet

When an employer health plan removes a drug from its formulary or excludes a drug class entirely, the financial consequences are immediate and stark. Understanding the specific cost scenarios helps you prepare rather than react.

Scenario 1: Full Formulary Exclusion

If your employer plan excludes GLP-1 medications entirely, your insurance will not apply any payment toward the drug cost. You would pay the full retail or negotiated pharmacy price. At major retail pharmacies, Wegovy lists at approximately $1,349 per month and Ozempic at approximately $968 per month without insurance, based on current list pricing tracked by GoodRx and manufacturer sources.

Scenario 2: Prior Authorization Tightening

Some employers won't eliminate coverage outright but will add stricter prior authorization requirements — such as mandatory BMI thresholds, documentation of failed lifestyle interventions, or co-occurring condition requirements. In practice, this can achieve a similar outcome: many patients who were previously covered will no longer qualify, shifting cost burden to the individual.

Scenario 3: Tier Reclassification

A less visible but still financially painful move is reclassifying GLP-1 drugs from a preferred tier (Tier 2 or Tier 3) to a specialty tier (Tier 4 or Tier 5). Specialty tier cost-sharing typically ranges from 25% to 33% coinsurance, which on a $1,300/month drug translates to $325–$430 in monthly out-of-pocket costs even with active coverage. Use our GLP-1 cost calculator to model how tier changes affect your specific monthly costs.

How Much Could You Actually Pay Out of Pocket in 2027?

The answer depends heavily on which drug you take, your state, and what alternatives you pursue. Below is a realistic range of what uninsured or underinsured GLP-1 patients may face.

GLP-1 Drug Monthly Cost Benchmarks (No Insurance)

• Semaglutide (Wegovy 2.4mg): ~$1,349/month at list price
• Semaglutide (Ozempic 1mg, off-label weight use): ~$968/month
• Tirzepatide (Zepbound 15mg): ~$1,059/month
• Tirzepatide (Mounjaro 15mg): ~$1,023/month
• Dulaglutide (Trulicity): ~$900–$950/month

These figures reflect retail list prices and can vary by pharmacy, location, and supply chain factors. Manufacturer savings programs and pharmacy discount cards can reduce these numbers significantly — but eligibility rules and income criteria apply.

Annual Cost Exposure Without Employer Coverage

At $1,000–$1,350 per month, an uninsured patient using a GLP-1 medication faces $12,000 to $16,200 annually in out-of-pocket drug costs. For context, the CMS National Health Expenditure data consistently shows prescription drug spending as one of the highest-growth categories in personal healthcare expenditure — and GLP-1s are now a primary driver of that trend.

Want to see what you'd specifically pay based on your plan type and drug? Run a detailed estimate using the GLP-1 out-of-pocket cost calculator at glp1costcalculator.com.

Alternatives and Cost Reduction Strategies If Your Employer Drops Coverage

Losing employer coverage does not necessarily mean losing access — but it does require proactive strategy. Several legitimate pathways exist to manage costs.

Manufacturer Patient Assistance Programs

Both Novo Nordisk (Wegovy/Ozempic) and Eli Lilly (Zepbound/Mounjaro) operate savings programs for eligible patients. Novo Nordisk's NovoCare program and Lilly's LillyConnect program offer monthly savings cards that can reduce out-of-pocket cost to as low as $25–$99 per month for commercially insured patients who meet eligibility criteria. Importantly, these programs are typically not available to patients on Medicare or Medicaid.

Marketplace (ACA Exchange) Plans

If you lose employer-sponsored coverage or your employer drops the specific drug class, it's worth comparing individual marketplace plans during open enrollment. Some ACA plans include GLP-1 drugs on their formulary, though coverage varies significantly by insurer and plan tier. The CMS Health Insurance Marketplace provides a searchable formulary comparison tool that can help identify plans covering your specific medication.

Compounded Semaglutide (Temporary Availability)

During periods of FDA-declared shortage, compounding pharmacies have legally supplied semaglutide at substantially lower prices — often $200–$400 per month. However, as of 2025, the FDA shortage designation for branded semaglutide products has been contested, and compounded availability may be legally restricted by the time 2027 plan year changes take effect. This should not be counted as a reliable long-term cost strategy.

Telehealth GLP-1 Prescribing Platforms

Several telehealth platforms have emerged offering GLP-1 prescriptions bundled with clinical support and, in some cases, lower-cost access through compounding or manufacturer partnerships. Pricing varies widely and the regulatory landscape for compounding-based offerings is evolving rapidly through 2025 and 2026.

How to Audit Your Current Employer Plan Before 2027

The most important thing you can do right now is understand exactly what your current plan covers and when changes take effect. Here's a practical checklist:

• Request the Summary Plan Description (SPD): This legally required document specifies drug coverage, tier placement, and exclusions. HR is required to provide it.
• Check the formulary annually: Plans can update formularies mid-year in some circumstances, and nearly always at open enrollment. Verify your drug's tier status each fall.
• Ask HR about 2026 open enrollment changes early: Many employers communicate benefit changes 60–90 days before enrollment opens. Asking early gives you more planning time.
• Understand your plan's specialty tier coinsurance caps: Some plans cap out-of-pocket specialty drug costs, which meaningfully changes the math on tier reclassification scenarios.
• Model your scenarios before open enrollment closes: Use a GLP-1 cost calculator to compare what different plan elections would mean for your annual drug spending.

Frequently Asked Questions

If my employer drops GLP-1 coverage in 2027, can I keep my current prescription?

Your prescription itself remains valid regardless of what your employer plan covers — the prescribing relationship with your physician is separate from your insurance coverage. What changes is who pays for it. You can continue filling the prescription, but you'll be responsible for the full cost unless you qualify for a manufacturer savings program, use a discount card, or obtain coverage through an alternative insurance source.

Are GLP-1 drugs covered by Medicare, and will that change in 2027?

As of 2025, Medicare Part D covers GLP-1 drugs prescribed for Type 2 diabetes (such as Ozempic and Mounjaro) but generally does not cover them for weight loss alone (such as Wegovy and Zepbound). Legislative proposals to expand Medicare coverage for anti-obesity medications have been introduced in Congress but have not passed as of this writing. Any changes to Medicare coverage policy would be significant for the approximately 65 million Americans enrolled in the program. Monitor CMS announcements for policy updates heading into 2026 and 2027.

What is the cheapest legitimate way to get GLP-1 drugs without employer insurance in 2027?

The lowest verified costs for eligible patients come from manufacturer patient assistance programs (PAPs), which can reduce costs to near zero for patients below certain income thresholds. For patients who don't qualify for PAPs, GoodRx coupons at specific pharmacies, warehouse club pharmacies like Costco or Sam's Club, and Mark Cuban's Cost Plus Drugs (for applicable drugs) can each offer meaningful discounts below retail list price. Exact savings vary by drug, dose, and location — running the numbers through a cost calculator before committing to a pharmacy can save hundreds of dollars per month.

How do I know if my employer is planning to drop GLP-1 coverage?

Employers are not required to announce benefit changes until the open enrollment window, though most provide advance notice. Proactive steps include reviewing your plan's annual Notice of Creditable Coverage, monitoring HR communications in early fall, and directly asking your HR or benefits administrator whether GLP-1 coverage is being evaluated for the upcoming plan year. If you depend on this medication, framing it as a health management question (rather than a cost complaint) often yields more useful responses.